Jubilant Organosys, an integrated pharmaceutical industry player, along with the University of Alabama at Birmingham (UAB), and Southern Research Institute today entered into a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases.

The latest move is an unique U. S.- India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.

Commenting on the development Shyam S. Bhartia, Chairman and Managing Director, and Hari S Bhartia, Co-chairman and Managing Director, Jubilant Organosys, said, “This novel academic and industrial collaboration demonstrates our commitment to partner with globally renowned academia in order to identify and deliver affordable innovation and healthcare solutions to the patients worldwide. We are happy to join hands with UAB and Southern Research Institute, known for its strengths in the areas of oncology, metabolic disease and infectious diseases. The collective innovation capabilities of this partnership further augments our mission to be the most innovative Drug Discovery and Development group in India, accelerating global drug development.”

Jubilant, through subsidiaries like Biosys, Chemsys and Clinsys, has developed strong partnerships in the area of research with leading academic institutions to support them in translation of early stage science and with innovative pharmaceutical companies to accelerate their drug discovery programs.

UAB receives more than $400 million annually in research grants and contracts and ranks in the top 25 nationally in National Institutes of Health (NIH) funding; it is a rich source of biological targets for drug development.

Southern Research Institute is a nonprofit 501(c) 3 scientific research organization that conducts preclinical drug discovery and development, and advanced engineering research in materials, systems development, environment and energy. It has earned worldwide acclaim for its success translating basic research into drugs that can be used to treat human illness, having discovered and helped move seven FDA-approved cancer drugs to market, with five more drugs in late- stage preclinical and early clinical studies.